Re: Leveraging AI to Revolutionize Cancer Detection and Care

Amsterdam, Dec 13th, 2024

To Whom it may concern,

Cancer ranks as the second leading cause of death worldwide, claiming approximately 9.6 million lives annually—about one in every six deaths, according to the WHO. Despite advancements in medical technology, the global cancer burden continues to rise, with tumor types like lung, colorectal, breast and prostate cancer dominating incidence and mortality statistics.

Early detection remains a critical factor in improving survival rates, yet significant gaps in diagnosis persist due to limitations in current screening methods and disparities in healthcare access.
Conventional tools such as mammograms, MRI, ultrasound, and biopsies, while effective, come with challenges: they can be invasive, costly, and subject to patient compliance issues. Additionally, factors like limited awareness, inadequate health education, false-negative results, and unequal access to routine checkups exacerbate the problem. These shortcomings highlight an urgent need for innovative solutions to identify individuals at high risk earlier and more efficiently.

Artificial intelligence (AI) is emerging as a transformative technology in cancer detection. By analyzing genetic information and risk factors, AI-driven models and software can pinpoint high-risk individuals with unprecedented accuracy. This proactive approach not only enhances early detection but also addresses disparities in access and outcomes, paving the way for more equitable healthcare solutions.
The integration of AI into screening programs holds enormous potential to optimize resources and reduce healthcare costs. As cancer incidence rises due to an aging population and longer life expectancy, healthcare systems face mounting pressure. AI-powered strategies can streamline case management, improve patient outcomes, and free up resources for further investment in advanced treatments, new technologies, and additional staff.
Incorporating AI into cancer care is not just a technological leap—it's a vital step toward meeting the growing global demand for healthcare while reducing costs and saving lives. This innovative approach promises to transform how hospitals and health systems worldwide address the cancer epidemic, ultimately benefiting millions.

I am delighted to support the **remarkable work led by Prof. Avan and his team of scientists and bioinformaticians, who have developed a ground-breaking AI-driven approach to identify individuals at risk of developing cancers** such as breast, prostate, colorectal, and cervical/ovarian cancers (https://smartcancer.ir/). This pioneering study represents a world-first effort to integrate multiple screening modalities into a holistic framework, utilizing AI-based digital analysis to assess risk and identify high-risk cases.

Location VUmc
De Boelelaan 1117
1081 HV Amsterdam
The Netherlands
T +31(0)20 444 4444

P.O. Box 7057
1007 MB Amsterdam
The Netherlands
www.amsterdamumc.nl

Location AMC
Meibergdreef 9
1105 AZ Amsterdam
The Netherlands
T +31(0)20 566 9111

P.O. Box 22660
1100 DD Amsterdam
The Netherlands
www.amsterdamumc.nl

By applying advanced analytics, this technology has the potential to enhance the diagnostic utility of screening programs significantly. As a result, cancer researchers and clinicians regard this initiative as a transformative step toward redefining current risk assessment guidelines.

Should you require further information, I would be more than happy to be contacted to provide additional details.

Yours sincerely,

Professor Elisa Giovannetti, MD, PhD
Head, Molecular Mechanisms of Drug Activity Group
Department of Medical Oncology / Lab. Medical Oncology
Amsterdam University Medical Centers, VU University, Amsterdam, NL
De Boelelaan 1118, 1081 HZ Amsterdam, The Netherlands
E: e.giovannetti@amsterdamumc.nl